Mbarara University of Science and Technology, Mbarara, Uganda.
Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
J Int AIDS Soc. 2022 Mar;25(3):e25894. doi: 10.1002/jia2.25894.
Antiretroviral pre-exposure prophylaxis (PrEP) may reduce periconception and pregnancy HIV incidence among women in settings, where gender power imbalances limit HIV testing, engagement in care and HIV viral suppression. We conducted qualitative interviews to understand factors influencing periconception and pregnancy PrEP uptake and use in a cohort of women (Trial registration: NCT03832530) offered safer conception counselling in rural Southwestern Uganda, where PrEP uptake was high.
Between March 2018 and January 2019, in-depth interviews informed by conceptual frameworks for periconception risk reduction and PrEP adherence were conducted with 37 women including those with ≥80% and <80% adherence to PrEP doses measured by electronic pill cap, those who never initiated PrEP, and seven of their male partners. Content and dyadic analyses were conducted to identify emergent challenges and facilitators of PrEP use within individual and couple narratives.
The median age for women was 33 years (IQR 28, 35), 97% felt likely to acquire HIV and 89% initiated PrEP. Individual-level barriers included unwillingness to take daily pills while healthy, side effects and alcohol use. Women overcame these barriers through personal desires to have control over their HIV serostatus, produce HIV-negative children and prevent HIV transmission within partnerships. Couple-level barriers included nondisclosure, mistrust and gender-based violence; facilitators included shared goals and perceived HIV protection, which improved communication, sexual intimacy and emotional support within partnerships through a self-controlled method. Community-level barriers included multi-level stigma related to HIV, ARVs/PrEP and serodifference; facilitators included active peer, family or healthcare provider support as women aspired to safely meet socio-cultural expectations to conceive and preserve serodifferent relationships. Confidence in PrEP effectiveness was promoted by positive peer experiences with PrEP and ongoing HIV testing.
Multi-level forms of HIV-, serodifference- and disclosure-related stigma, side effects, pill burden, alcohol use, relationship dynamics, social, professional and partnership support towards adaptation and HIV risk reduction influence PrEP uptake and adherence among HIV-negative women with plans for pregnancy in rural Southwestern Uganda. Confidence in PrEP, individually controlled HIV prevention and improved partnership communication and intimacy promoted PrEP adherence. Supporting individuals to overcome context-specific barriers to PrEP use may be an important approach to improving uptake and prolonged use.
抗逆转录病毒药物事前预防(PrEP)可能会降低在那些性别权力失衡限制艾滋病毒检测、参与治疗和艾滋病毒病毒抑制的环境中,女性在围孕期和孕期的艾滋病毒发病率。我们进行了定性访谈,以了解在乌干达西南部农村地区的一个队列中,影响围孕期和孕期接受 PrEP 治疗的因素,该队列为女性提供了更安全的受孕咨询,那里 PrEP 的接受率很高。
2018 年 3 月至 2019 年 1 月,根据围孕期风险降低和 PrEP 依从性的概念框架,对 37 名妇女进行了深入访谈,包括那些电子药盒记录的 PrEP 剂量服用率≥80%和<80%的妇女、从未开始服用 PrEP 的妇女以及她们的 7 名男性伴侣。对个人和夫妻的叙述进行内容和对偶分析,以确定 PrEP 使用中的潜在挑战和促进因素。
妇女的中位年龄为 33 岁(IQR 28,35),97%的人认为有可能感染艾滋病毒,89%的人开始服用 PrEP。个人层面的障碍包括在健康时不愿意每天服用药丸、副作用和饮酒。妇女通过个人控制 HIV 感染状况、生育 HIV 阴性婴儿和预防伴侣间 HIV 传播的愿望克服了这些障碍。夫妻层面的障碍包括不披露、不信任和基于性别的暴力;促进因素包括共同的目标和对 HIV 保护的感知,这通过自我控制的方法改善了伴侣关系中的沟通、性亲密和情感支持。社区层面的障碍包括与 HIV、抗逆转录病毒药物/PrEP 和血清差异相关的多层次耻辱感;促进因素包括积极的同伴、家庭或医疗保健提供者的支持,因为妇女渴望安全地满足社会文化期望,以实现受孕和维持血清不同的关系。对 PrEP 有效性的信心来自于对 PrEP 和持续艾滋病毒检测的积极同伴经验。
HIV、血清差异和披露相关耻辱感、副作用、药丸负担、饮酒、关系动态、社会、专业和伙伴关系支持的多层次形式,以及对适应和降低 HIV 风险的支持,影响了乌干达西南部农村地区计划怀孕的 HIV 阴性妇女对 PrEP 的接受和坚持。对 PrEP 的信心、个人控制的 HIV 预防以及改善的伙伴关系沟通和亲密关系促进了 PrEP 的坚持。支持个人克服 PrEP 使用方面的具体情况障碍可能是提高接受度和延长使用时间的重要方法。